Investigators conducting an online survey to gather information from people with inclusion-body myositis report early results and ask a few more questions
Investigators conducting an online survey launched in January 2013 to gather anonymous information from people with inclusion-body myositis (IBM) are now reporting preliminary results and are asking the original respondents to complete a short supplementary survey.
MDA-supported biotechnology company Summit PLC and the University of Oxford will collaborate on development of utrophin modulators to treat Duchenne/Becker MD
MDA-supported biotechnology company Summit PLC has entered into a collaboration with the University of Oxford (United Kingdom) for continued development of utrophin modulators to treat Duchenne muscular dystrophy (DMD) and possibly Becker muscular dystrophy (BMD).
Researchers supported in part by MDA have identified antibodies to the LRP4 protein as a third known cause of myasthenia gravis
A research team supported in part by MDA has shown that an abnormal reaction of the immune system against a protein called LRP4 can be added to the known causes of myasthenia gravis (MG), a disorder involving fluctuating weakness and fatigue because of impaired nerve-to-muscle communication. MG is an autoimmune disease, meaning it's caused by abnormal activity of the body's immune system against...
Biotech company Prosensa says an analysis of drisapersen trials in Duchenne muscular dystrophy and a DMD natural history study will guide future exon-skipping drug trials
In a Nov.
A study to determine the natural history and outcome measures for clinical trials in Becker MD and sporadic (nongenetic) inclusion-body myositis is open in Ohio
A study to determine the best outcome measures — ways to evaluate the effects of a treatment — for use in clinical studies in Becker muscular dystrophy (BMD) and sporadic (nongenetic) inclusion-body myositis (sIBM) is underway at Nationwide Children's Hospital in Columbus, Ohio, under the supervision of neurologist Jerry Mendell working with physical therapists Linda Lowes and
Prosensa and GlaxoSmithKline aim to enroll 250 participants in a study to determine the usual progression of Duchenne muscular dystrophy and aid clinical trials
Dutch biotechnology company Prosensa and multinational pharmaceutical company GlaxoSmithKline (GSK) are seeking participants with Duchenne muscular dystrophy (DMD) who are 3-18 years old for a large-scale study of the disorder's "natural history" (usual course over time).